- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06132776
The Mamma HiToP Study
High Tone Therapy for Chemotherapy-induced Neuropathy in Breast Cancer Patients
The HiToP ® 191 PNP an certified device licensed for the treatment of neuropathia.
The home-based treatment is to be performed only in accordance with the approved Investigational Plan (CIP) on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
The study is multicenter, randomized, double-blind, and placebo-controlled.
Primary Objective: Comparison of the change of paresthesias from baseline until end of therapy between the two patient groups, assessed by questionnaires
Secondary Objectives: Further symptoms of neuropathy as well as on health-related quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Robert Wakolbinger-Habel, MD, PhD
- Phone Number: +43 1 28802 4604
- Email: robert.wakolbinger-habel@gesundheitsverbund.at
Study Contact Backup
- Name: Brigitte E Scheffold, MD, MSc, MSc
- Phone Number: +43 1 28802 4604
- Email: brigitteelisabeth.scheffold@gesundheitsverbund.at
Study Locations
-
-
-
Vienna, Austria
- Recruiting
- Clinics Donaustadt, Ottakring, Hietzing
-
Contact:
- Robert Wakolbinger-Habel, MD, PhD
- Phone Number: 4604 +43 1 28802
- Email: robert.wakolbinger-habel@gesundheitsverbund.at
-
Contact:
- Brigitte E Scheffold, MD, MSc, MSc
- Phone Number: 4604 +43 1 28802
- Email: brigitteelisabeth.scheffold@gesundheitsverbund.at
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- - Patients with histologically verified breast cancer and neoadjuvant or adjuvant treatment with a taxane derivate (e.g., Paclitaxel, Docetaxel): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9.
- Cumulative dose of at least 3 cycles
- Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects
- Life expectancy of at least 3 months
- Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying)
- Ability to walk (with or without aids)
- European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2
- Intensity of paresthesias of > 3/10 on the Visual Analog Scale (VAS)
Exclusion Criteria:
- - Prevalent neuropathy of different etiology
- Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators
- Epilepsy
- Minors or persons unable to give informed consent
- Current neurotoxic medication
- Implanted pacemakers or defibrillators
- Pregnancy
- Wounds in the area to be treated, acute local or systemic infection
- Peripheral arterial occlusive disease > grade 2
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo group
|
Placebo therapy
|
Experimental: Verum group
|
High tone therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Alleviation of paresthesias (VAS)
Time Frame: baseline vs. one day after the last treatment session
|
baseline vs. one day after the last treatment session
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Further neuropathic symptoms (via VAS questionnaire)
Time Frame: baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
e.g., intensity of tightness, cramps
|
baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
Further neuropathic symptoms (via EORCT CIPN20 questionnaire)
Time Frame: baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
sensory, motor and autonomic scale
|
baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
Quality of life (via EORCT C30 questionnaire)
Time Frame: baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
global health status, physical function, symptom scales
|
baseline vs. one day after the last treatment session vs. follow-up 2 weeks after the last treatment session
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Tatjana Paternostro-Sluga, MD, Vienna Healthcare Group
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP_Mamma 1.1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chemotherapy-induced Peripheral Neuropathy
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Leiden University Medical Center; Reinier de GraafRecruitingChemotherapy-induced Peripheral Neuropathy | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Qutenza | DuloxetineNetherlands
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Institut Cancerologie de l'OuestGrünenthal GmbHNot yet recruitingChemotherapy-induced Peripheral Neuropathy
-
Odense University HospitalAarhus University Hospital; University of Southern Denmark; Sygehus LillebaeltRecruitingChemotherapy-induced Peripheral NeuropathyDenmark
-
WinSanTor, IncRecruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
Veloxis PharmaceuticalsRecruitingChemotherapy-induced Peripheral NeuropathyUnited States, Japan
-
National University Hospital, SingaporePaxman Coolers Ltd.; The N.1 Institute for Health, National University of SingaporeRecruitingChemotherapy-induced Peripheral NeuropathySingapore
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)RecruitingChemotherapy-Induced Peripheral NeuropathyUnited States
-
Donna Hammond, PhDActive, not recruitingChemotherapy-induced Peripheral NeuropathyUnited States
-
University of Rochester NCORP Research BaseNational Cancer Institute (NCI)CompletedEffects of Transcutaneous Electrical Nerve Stimulation on Chemotherapy-Induced Peripheral NeuropathyChemotherapy-Induced Peripheral NeuropathyUnited States
Clinical Trials on HiToP 191 PNP
-
West German Center of Diabetes and Healthgbo Medizintechnik AGCompleted
-
West German Center of Diabetes and Healthgbo Medizintechnik AGCompletedChronic Radicular Back Pain | Lumboischialgia | Cervico BrachialgiaGermany
-
Vienna Hospital AssociationCompletedElectrical Stimulation | Chemotherapy-induced Peripheral NeuropathyAustria
-
Paracelsus Medical UniversitySalzburger LandesklinikenCompletedPeripheral Nervous System ProblemAustria
-
Regeneron PharmaceuticalsRecruitingHealthy Volunteers | Non-alcoholic Fatty Liver Disease (NAFLD)United States
-
Regeneron PharmaceuticalsNot yet recruitingNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD) | Genetic Risk Factor
-
UniQure Biopharma B.V.Not yet recruiting
-
National Cancer Institute (NCI)CompletedUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Samyang Biopharmaceuticals CorporationCompleted
-
Samyang Biopharmaceuticals CorporationCompleted